A First-in-Human Study of CEE321 in Adult Subjects

Completed · Phase 1

Conditions studied: Atopic Dermatitis

In brief

Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects and Subjects with Atopic Dermatitis

Key facts

Study ID

NCT04612062

Run by

Novartis Pharmaceuticals

People needed

28

Starts

2020-02-27

Expected to finish

2021-05-16

Last updated by the study team

2022-10-28

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

Where it is running

• Novartis Investigative Site — Glendale, California, United States
• Novartis Investigative Site — Baltimore, Maryland, United States
• Novartis Investigative Site — Hachiōji, Tokyo, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.